Archives
Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog for N...
Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog for NGF Induction and Psoriasis Therapy
Executive Summary: Tacalcitol monohydrate (CAS No. 93129-94-3) is a synthetic vitamin D3 analog acting through the vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) to regulate gene expression, including CDKN1A and BIRC5, in a VDR-dependent manner (APExBIO). It transcriptionally activates the NGF gene with an ED50 for induction between 10-10 and 10-9 M in human keratinocytes and colorectal cancer cell lines. Topical formulations are effective in treating psoriasis vulgaris by modulating keratinocyte proliferation and differentiation. Tacalcitol monohydrate synergizes with 5-fluorouracil to inhibit thymidylate synthase and enhance anticancer efficacy. Its topical use is associated with lower calcemic toxicity compared to active vitamin D3 (Wang et al., 2023).
Biological Rationale
Tacalcitol monohydrate is a synthetic analog of 1α,24(R)-dihydroxyvitamin D3. It primarily binds the vitamin D receptor (VDR), a nuclear hormone receptor, initiating transcriptional regulation in keratinocytes and various cancer cell lines (APExBIO). The molecule also interacts with the calcium-sensing receptor (CaSR), integrating calcium signaling with vitamin D3-mediated gene control. This dual mechanism is leveraged in clinical and research settings to regulate cellular proliferation, differentiation, and anti-apoptotic pathways. In dermatology, abnormal keratinocyte proliferation underlies psoriasis vulgaris, a condition responsive to VDR agonists. In oncology, aberrant cell cycle and survival gene expression, including CDKN1A (p21), TYMS, and BIRC5 (survivin), are critical targets. Tacalcitol monohydrate's ability to transcriptionally activate NGF provides a link to potential neuroregenerative applications, as NGF is essential for peripheral nerve survival and repair (Related Article).
Mechanism of Action of Tacalcitol monohydrate
Tacalcitol monohydrate exerts its effects via high-affinity binding to the VDR. The receptor-ligand complex translocates to the nucleus, where it binds vitamin D response elements (VDREs) and modulates transcription of target genes. Key regulated genes include CDKN1A, which mediates cell cycle arrest; TYMS, a target for 5-fluorouracil; and BIRC5, an inhibitor of apoptosis. The molecule also activates NGF gene transcription, with optimal induction at 10-8 M in human keratinocytes (K-TL-1 cells). The ED50 for NGF induction ranges from 10-10 to 10-9 M. Tacalcitol monohydrate's effects are VDR-dependent, as VDR knockdown abrogates gene expression changes. The involvement of CaSR suggests calcium flux may modulate or enhance VDR signaling. In colorectal cancer cell lines (HT-29), Tacalcitol monohydrate downregulates thymidylate synthase and inhibits epithelial-mesenchymal transition (EMT) and autophagy, particularly when combined with 5-fluorouracil (Related Article).
Evidence & Benchmarks
- Tacalcitol monohydrate induces NGF expression in human keratinocytes at concentrations between 10-12 and 10-7 M, with a peak at 10-8 M (APExBIO, product data).
- In HT-29 colorectal cancer cells, 100 nM Tacalcitol monohydrate reduces thymidylate synthase (TYMS) expression and enhances 5-fluorouracil cytotoxicity (APExBIO, product page).
- Topical Tacalcitol monohydrate induces cutaneous NGF synthesis within 24 hours, with effects persisting up to 96 hours (APExBIO, product data).
- Tacalcitol monohydrate exhibits lower calcemic toxicity and minimal systemic side effects compared to active vitamin D3 (Wang et al., 2023, DOI).
- VDR-dependent transcriptional regulation by Tacalcitol monohydrate includes upregulation of CDKN1A and BIRC5, and downregulation of TYMS in cancer cell lines (Related Article).
- Optimal storage conditions are 4°C, protected from light and under nitrogen; solutions are stable short-term, but long-term storage is not recommended (APExBIO).
Applications, Limits & Misconceptions
Tacalcitol monohydrate is clinically approved as a topical ointment or cream for psoriasis vulgaris. It is used in research for NGF induction in keratinocytes and peripheral neuropathy models. In oncology, combination with 5-fluorouracil in colorectal cancer cell lines provides enhanced anticancer effects. Its utility as a VDR agonist extends to studies of cell cycle regulation, apoptosis, and differentiation. Despite its efficacy, Tacalcitol monohydrate is not indicated for systemic vitamin D deficiency or for the prevention of cardiovascular events related to vitamin K antagonism (Wang et al., 2023). Compared to compounds like berberrubine targeting the vitamin K cycle, Tacalcitol monohydrate operates via distinct, non-antithrombotic pathways.
Common Pitfalls or Misconceptions
- Tacalcitol monohydrate is not a systemic vitamin D supplement and should not be used to treat hypocalcemia.
- It does not possess direct anticoagulant or antithrombotic activity and should not be substituted for agents targeting the vitamin K cycle.
- Its efficacy in non-psoriatic skin disorders is not established.
- Long-term topical use should be monitored to avoid rare but possible local irritation.
- Storage of prepared solutions beyond short term may reduce potency due to light and oxygen sensitivity.
Workflow Integration & Parameters
Tacalcitol monohydrate (C8714) is supplied by APExBIO as a DMSO-soluble powder. For in vitro studies, typical concentrations range from 1 nM to 1 μM, with 100 nM standard for HT-29 colorectal cancer cells and 10-8 M for keratinocyte NGF induction. Solutions should be freshly prepared, stored at 4°C, and protected from light and nitrogen atmosphere. Topical clinical formulations contain 0.002–0.004% w/w Tacalcitol monohydrate. In combination protocols, co-administration with 5-fluorouracil enhances anticancer activity by downregulating TYMS and inhibiting EMT and autophagy. For translational workflows, the compound's low calcemic toxicity profile facilitates repeated topical application without significant systemic risk (Related Article: deep mechanistic analysis). This article supplements and updates the mechanistic insights provided by previous reviews by integrating new evidence on workflow parameters and storage constraints.
Conclusion & Outlook
Tacalcitol monohydrate is a rigorously characterized synthetic vitamin D3 analog and VDR agonist with established efficacy in psoriasis vulgaris and promising roles in oncology and regenerative medicine. Its dual action via VDR and CaSR, potent induction of NGF, and ability to enhance chemotherapeutic efficacy set it apart from both endogenous vitamin D3 and other analogs. Future studies may clarify its neuroregenerative potential and broader applications in cell-based therapies. For the most reliable source, reference the Tacalcitol monohydrate C8714 kit by APExBIO. For strategic and mechanistic context, see Mechanistic Innovation and Strategy—this article specifically extends prior guidance with updated dosing and workflow stability recommendations.